| Critical Path for Rare Neurodegenerative Diseases |
Research Initiative |
FDA |
NINDS |
Critical Path for Rare Neurodegenerative Diseases is a public-private partnership aimed at advancing the understanding of neurodegenerative diseases and supporting the development and regulatory review of treatments for amyotrophic lateral sclerosis (ALS) and other rare neurodegenerative diseases. |
| Cross Federal Workgroup on Telehealth |
Committee, Work group, Advisory group, or Task Force |
HRSA, AHRQ, CDC, CMS, FDA, HRSA, IHS |
NIDA |
The goal of this work group is to develop a coordinated view of what the Federal government is undertaking in telehealth, in an effort to identify possible collaboration mechanisms and share lessons learned across multiple agencies. |
| Cross HHS Primary Care Research Workgroup Meeting |
Committee, Work group, Advisory group, or Task Force |
AHRQ, ACF, AHRQ, ASPR, CDC, CMS, HRSA, IHS, OS |
NINR, OD/DPCPSI |
Supporting collaboration/coordination of primary care research efforts across HHS |
| CTAC Ad hoc Strategic Planning Working Group |
Committee, Work group, Advisory group, or Task Force |
CMS, FDA |
NCI |
The CTAC SPWG was charged to re-assess NCI’s strategic vision for its clinical trials system for 2030 and beyond. The Working Group will review and address the capabilities of the clinical trials infrastructure necessary for achieving this vision as well as consider recommendations for relevant future CTAC activities. |
| CTAC ad hoc Working Group on Streamlining Clinical Trials |
Committee, Work group, Advisory group, or Task Force |
FDA |
NCI |
The CTAC Streamlining Clinical Trials Working Group will address the implementation of the CTAC Strategic Planning Working Group’s recommendations around streamlining NCI’s clinical trials. The Working Group will advise NCI on ways to limit data collection in clinical trials as well as optimize the utilization of Electronic Health Records (EHRs) to support clinical trials.*The working group released its interim report in FY2023. |
| CURE ID |
Research Initiative |
FDA |
NCATS |
CURE ID is a public repository that reports novel uses of existing drugs for difficult-to-treat diseases through a website, a smartphone or other mobile device. The platform enables the crowdsourcing of medical information from health care providers, patients and care partners to help facilitate the development of new treatments for diseases that lack approved therapies. CURE ID is a collaboration between the FDA and the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH). FDA and NIH are also collaborating with academic, medical societies and patient organizations to optimize the entry of information into CURE ID as well as provide the information on novel uses of existing drugs back to the public. |
| Cytokine Interest Group |
Committee, Work group, Advisory group, or Task Force |
FDA |
NCI, NEI, NHGRI, NIA, NIAID, NIAMS, NIDCD |
The Cytokine Interest Group brings together NIH and FDA scientists from many different areas working with cytokines as mediators of immune processes. It provides a platform for establishing networks for the exchange of ideas and reagents. Its activities comprise multiple minisymposia throughout the year and an award for the best paper in cytokine research for postdoctoral fellows working at the NIH or FDA. |
| DailyMed |
Resource Development |
FDA |
NLM |
DailyMed is an online database maintained by the National Library of Medicine (NLM) that provides high-quality information on marketed drugs, including FDA labeling information (package inserts). DailyMed provides health care providers, information professionals, researchers, and the public with a standard, comprehensive, up-to-date resource for accessing and downloading medication content and labeling as found in medication package inserts. http://www.dailymed.nlm.nih.gov |
| Data-Sharing Meeting |
Committee, Work group, Advisory group, or Task Force |
FDA |
NIDA |
Collaboration description: This meeting between NIDA, FDA, and DEA convenes three times per year to discuss emerging abuse-liability data relevant to the scheduling of psychoactive substances. NIDA DTMC’s Addiction Treatment Discovery Program often shares drug discrimination and locomotor activity data collected on these substances (presented by Carol Hubner). These data are used to inform scheduling decisions and are at times included in Eight Factor Analyses. |
| Department of Health and Human Services (DHHS) Medical Claims Review Panel |
Committee, Work group, Advisory group, or Task Force |
OS, AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA |
CC |
The Medical Claims Review Panel (MCRP) assists the Department of Health and Human Services (DHHS) in meeting its responsibility to provide quality health care in its facilities and by its practitioners. The MCRP reviews paid claims against DHHS facilities and providers to determine if the care provided met the standard of care and makes quality improvement recommendations to health care facilities and individual providers. The Panel meets monthly and includes two National Institutes Health (NIH) representatives; the current Chair of the Panel is an NIH physician. |